These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 1384145)
21. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors. Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937 [TBL] [Abstract][Full Text] [Related]
22. One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site. Greco FA; Hainsworth JD Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-101-S19-105. PubMed ID: 9427278 [TBL] [Abstract][Full Text] [Related]
23. [Non-testicular germ cell tumors: analysis of the therapy study MAKEI 83/86 anc changes in the protocol for the follow-up study]. Göbel U; Bamberg M; Haas RJ; Bökkerink JP; Brämswig G; Calaminus G; Engert J; Gadner H; Havers W; Janka-Schaub GE Klin Padiatr; 1989; 201(4):247-60. PubMed ID: 2476583 [TBL] [Abstract][Full Text] [Related]
24. Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989). Motzer RJ; Geller NL; Tan CC; Herr H; Morse M; Fair W; Sheinfeld J; Sogani P; Russo P; Bosl GJ Cancer; 1991 Mar; 67(5):1305-10. PubMed ID: 1703917 [TBL] [Abstract][Full Text] [Related]
25. Alternating combination chemotherapy in patients with extragonadal germ cell tumors. A Southwest Oncology Group study. Bukowski RM; Wolf M; Kulander BG; Montie J; Crawford ED; Blumenstein B Cancer; 1993 Apr; 71(8):2631-8. PubMed ID: 7680950 [TBL] [Abstract][Full Text] [Related]
26. Treatment of favorable-prognosis nonseminomatous testicular germ cell tumors with etoposide, cisplatin, and reduced dose of bleomycin. Brada M; Horwich A; Peckham MJ Cancer Treat Rep; 1987 Jun; 71(6):655-6. PubMed ID: 2438041 [TBL] [Abstract][Full Text] [Related]
27. Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study. Saghatchian M; Fizazi K; Borel C; Ducreux M; Ruffié P; Le Chevalier T; Théodore C Ann Oncol; 2001 Apr; 12(4):535-40. PubMed ID: 11398889 [TBL] [Abstract][Full Text] [Related]
28. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. Ozols RF; Ihde DC; Linehan WM; Jacob J; Ostchega Y; Young RC J Clin Oncol; 1988 Jun; 6(6):1031-40. PubMed ID: 2453619 [TBL] [Abstract][Full Text] [Related]
29. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP; J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419 [TBL] [Abstract][Full Text] [Related]
30. Carcinoma of unknown primary: identification of a treatable subset? van der Gaast A; Verweij J; Henzen-Logmans SC; Rodenburg CJ; Stoter G Ann Oncol; 1990; 1(2):119-22. PubMed ID: 1706613 [TBL] [Abstract][Full Text] [Related]
31. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis. Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800 [TBL] [Abstract][Full Text] [Related]
32. Etoposide, cisplatin, bleomycin, and cyclophosphamide (ECBC) as first-line chemotherapy for poor-risk non-seminomatous germ cell tumors. Gerl A; Clemm C; Hentrich M; Hartenstein R; Wilmanns W Acta Oncol; 1993; 32(5):541-6. PubMed ID: 7692901 [TBL] [Abstract][Full Text] [Related]
34. Adequacy of chemotherapy prior to cytoreductive surgery in testicular carcinoma. Kennedy BJ; Torkelson JL; Fraley EE Am J Clin Oncol; 1996 Dec; 19(6):541-5. PubMed ID: 8931667 [TBL] [Abstract][Full Text] [Related]
35. [New salvage chemotherapy (cisplatin, adriamycin, bleomycin, methotrexate, etoposide) for advanced nonseminomatous testicular cancer: experience in three cases]. Ikeda I; Shuin T; Yao M; Kubota Y; Hosaka M Hinyokika Kiyo; 1993 Mar; 39(3):237-42. PubMed ID: 7685142 [TBL] [Abstract][Full Text] [Related]
36. [A Case of Poorly Differentiated Carcinoma of Unknown Primary Site with Risk of Choriocarcinoma Syndrome Effectively Treated with Reduced Bleomycin,Cisplatin ,Etoposide Combination Regimen(BEP Regimen)]. Okano M; Oda H; Ishihara M; Tamaru S; Saito K; Yamashita Y; Mizuno T; Katayama N Gan To Kagaku Ryoho; 2018 Apr; 45(4):643-645. PubMed ID: 29650822 [TBL] [Abstract][Full Text] [Related]
37. Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. Greco FA; Vaughn WK; Hainsworth JD Ann Intern Med; 1986 Apr; 104(4):547-53. PubMed ID: 3006571 [TBL] [Abstract][Full Text] [Related]
38. High complete response rate in children with advanced germ cell tumors using cisplatin-containing combination chemotherapy. Pinkerton CR; Pritchard J; Spitz L J Clin Oncol; 1986 Feb; 4(2):194-9. PubMed ID: 2418168 [TBL] [Abstract][Full Text] [Related]
39. Etoposide and cisplatin with or without bleomycin as first-line chemotherapy for patients with small-volume metastases of testicular nonseminoma. Peckham MJ; Horwich A; Blackmore C; Hendry WF Cancer Treat Rep; 1985 May; 69(5):483-8. PubMed ID: 2408750 [TBL] [Abstract][Full Text] [Related]
40. Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience. Motzer RJ; Bajorin DF; Vlamis V; Weisen S; Bosl GJ Semin Oncol; 1992 Dec; 19(6 Suppl 12):8-11. PubMed ID: 1336624 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]